TY - JOUR
T1 - The use of mucoadhesive oral patches containing epigallocatechin-3-gallate to treat periodontitis
T2 - an in vivo study
AU - Lashari, Dur Muhammad
AU - Aljunaid, Mohammed
AU - Lashari, Yasmeen
AU - Qaid, Huda Rashad
AU - Ridwan, Rini Devijanti
AU - Diyatri, Indeswati
AU - Kaid, Nejva
AU - Alkadasi, Baleegh Abdulraoof
N1 - Publisher Copyright:
© 2022 [The Author/The Authors]
PY - 2022/12
Y1 - 2022/12
N2 - Objectives: The application of topical drugs such as mucoadhesive oral patches (MOPs) do not irritate the mucosa and are able to increase the permeability of drugs to oral tissue. Epigallocatechin-3-gallate (EGCG) is an active ingredient that exhibits significant antibacterial and anti-inflammatory effects. The purpose of this study was to analyze the therapeutic potential of a mucoadhesive oral patch containing EGCG (MOP-EGCG) in a model of periodontitis and investigate its effects on the expression of osteoprotegerin (OPG), receptor activator of nuclear factor-kappa Β ligand (RANKL) and receptor activator of nuclear factor-κB (RANK). Methods: A model of periodontitis was induced in Rattus novergicus used Porphyromonas gingivalis by applying 0.03 ml of bacteria locally with 1 × 1010 colony-forming units (CFU) seven times at 2-day intervals in the central lower incisors. Periodontitis was then treated with MOP (control), a mucoadhesive oral patch containing doxycycline (MOP-doxy) or MOP-EGCG for 1 h/day for 21 days. On days 3, 5, 7, 14 and 21 after treatment, the central lower incisor was biopsied and analyzed by immunohistochemistry for RANK/RANKL and OPG expression in the gingiva tissue. Results: MOP-EGCG extract significantly reduced the expression of RANKL and increased the expression of OPG and RANK (p < 0.05) when compared to the MOP-doxy and MOP groups. Conclusion: MOP-EGCG extract reduced the expression of RANKL and increased the expression of OPG and RANK, thus suggesting that MOP-EGCG can inhibit the loss of alveolar bone in periodontitis.
AB - Objectives: The application of topical drugs such as mucoadhesive oral patches (MOPs) do not irritate the mucosa and are able to increase the permeability of drugs to oral tissue. Epigallocatechin-3-gallate (EGCG) is an active ingredient that exhibits significant antibacterial and anti-inflammatory effects. The purpose of this study was to analyze the therapeutic potential of a mucoadhesive oral patch containing EGCG (MOP-EGCG) in a model of periodontitis and investigate its effects on the expression of osteoprotegerin (OPG), receptor activator of nuclear factor-kappa Β ligand (RANKL) and receptor activator of nuclear factor-κB (RANK). Methods: A model of periodontitis was induced in Rattus novergicus used Porphyromonas gingivalis by applying 0.03 ml of bacteria locally with 1 × 1010 colony-forming units (CFU) seven times at 2-day intervals in the central lower incisors. Periodontitis was then treated with MOP (control), a mucoadhesive oral patch containing doxycycline (MOP-doxy) or MOP-EGCG for 1 h/day for 21 days. On days 3, 5, 7, 14 and 21 after treatment, the central lower incisor was biopsied and analyzed by immunohistochemistry for RANK/RANKL and OPG expression in the gingiva tissue. Results: MOP-EGCG extract significantly reduced the expression of RANKL and increased the expression of OPG and RANK (p < 0.05) when compared to the MOP-doxy and MOP groups. Conclusion: MOP-EGCG extract reduced the expression of RANKL and increased the expression of OPG and RANK, thus suggesting that MOP-EGCG can inhibit the loss of alveolar bone in periodontitis.
KW - Bone loss
KW - Epigallocatechin-3-gallate
KW - Oral patch
KW - Periodontitis
KW - Porphyromonas gingivalis
UR - http://www.scopus.com/inward/record.url?scp=85134192021&partnerID=8YFLogxK
U2 - 10.1016/j.jtumed.2022.06.006
DO - 10.1016/j.jtumed.2022.06.006
M3 - Article
AN - SCOPUS:85134192021
SN - 1658-3612
VL - 17
SP - 1014
EP - 1020
JO - Journal of Taibah University Medical Sciences
JF - Journal of Taibah University Medical Sciences
IS - 6
ER -